GSK3882347
Phase 1Small molecule
GSKGSK3882347 is one of 36 small molecule programs targeting Urinary Tract Infection. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Medrol
PfizerPhase 3
Merrem
BB. Braun Medical Inc.
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Prulifloxacin
Merck & Co.Phase 3
Piperacillin/tazobactam
PfizerPhase 3
Amoxicillin/clavulanate Potassium
Johnson & JohnsonPhase 3
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
Amoxicillin/clavulanate
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Interaction1 trial
ART1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GSK3882347. EMBL-EBI & Wellcome Sanger Institute.
- [4]